In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products

被引：13

作者：

Sheu, Ming-Jen ^{[1
,2
]}

Chen, Chi-Chung ^{[3
,4
]}

Lu, Ying-Chen ^{[3
]}

Su, Bo-An ^{[5
]}

Zhang, Chun-Cheng ^{[5
]}

Wang, Shu-Shen ^{[5
]}

Chuang, Yin-Ching ^{[2
,4
]}

Tang, Hung-Jen ^{[5
]}

Lai, Chih-Cheng ^{[6
]}

机构：

[1] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan 710, Taiwan

[2] Chia Nan Univ Pharm & Sci, Dept Med Chem, Tainan 717, Taiwan

[3] Chi Mei Med Ctr, Dept Med Res, Tainan 710, Taiwan

[4] Natl Chiayi Univ, Dept Food Sci, Chiayi 717, Taiwan

[5] Chi Mei Med Ctr, Dept Internal Med, Tainan 710, Taiwan

[6] Kaohsiung Vet Gen Hosp, Dept Internal Med, Tainan Branch, Tainan 710, Taiwan

来源：

ANTIBIOTICS-BASEL | 2020年 / 9卷 / 02期

关键词：

cefoperazone; sulbactam; multidrug-resistant organism; antimicrobial activity; GENERIC ANTIBIOTICS; VANCOMYCIN; SULBACTAM; QUALITY; IMPACT;

D O I：

10.3390/antibiotics9020077

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

This study aims to assess the in vitro activity of different samples of cefoperazone/sulbactam (CFP/SUL) against multidrug-resistant organisms (MDROs). Clinical isolates of extended-spectrum beta-lactamase (ESBL)-Escherichia coli, ESBL-Klebsiella pneumoniae, carbapenem-resistant Acinetobacter baumannii (CR-AB), and carbapenem-resistant Pseudomonas aeruginosa (CR-PA) were collected. The minimum inhibitory concentration (MIC) and time-killing methods were used to assess and compare the in vitro activities of different samples of cefoperazone/sulbactam (CFP/SUL) against these MDROs. For ESBL-E. coli, ESBL-K. pneumoniae, and CR-PA, product C had smaller variations than product A and B (p < 0.05). For CR-AB, product B had the largest variation compared to the other two products (p < 0.05). In the time-killing studies, significant differences among the products when used at 16/16 mu g/mL were noted for ESBL-E. coli, ESBL-K. pneumoniae, and CR-AB isolates. In conclusion, this study demonstrated the significantly different activity of different products of CFP/SUL against MDROs.

引用

页数：8

共 18 条

[1] Even Apparently Insignificant Chemical Deviations among Bioequivalent Generic Antibiotics Can Lead to Therapeutic Nonequivalence: the Case of Meropenem [J].